tradingkey.logo
tradingkey.logo
Search

Ginkgo Bioworks Holdings Inc

DNA
Add to Watchlist
8.590USD
+0.250+3.00%
Close 05/13, 16:00ETQuotes delayed by 15 min
535.37MMarket Cap
LossP/E TTM

Ginkgo Bioworks Holdings Inc

8.590
+0.250+3.00%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+3.00%

5 Days

-14.78%

1 Month

+28.59%

6 Months

+7.38%

Year to Date

+3.37%

1 Year

+5.79%

Key Insights

Ginkgo Bioworks Holdings Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 170 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Sell, with the highest price target at 10.00.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ginkgo Bioworks Holdings Inc's Score

Industry at a Glance

Industry Ranking
170 / 383
Overall Ranking
305 / 4487
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Ginkgo Bioworks Holdings Inc Highlights

StrengthsRisks
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Fairly Valued
The company’s latest PE is -1.61, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 33.44M shares, decreasing 12.65% quarter-over-quarter.
Held by Murray Stahl
Star Investor Murray Stahl holds 5.89K shares of this stock.

Analyst Rating

Based on 3 analysts
Sell
Current Rating
10.000
Target Price
+15.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Ginkgo Bioworks Holdings Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Ginkgo Bioworks Holdings Inc Info

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Ticker SymbolDNA
CompanyGinkgo Bioworks Holdings Inc
CEOKelly (Jason)
Websitehttps://investors.ginkgobioworks.com/
KeyAI